Company Update: Abbott Laboratories (NYSE:ABT) – Promising Preliminary Data Show Abbott’s Innovative Testing Platform May Identify Life-Threatening Infections Faster Than Current Methods

[PR Newswire] – BARCELONA, Spain, May 12, 2014 /PRNewswire/ — Abbott (ABT) today announced initial results that suggest its innovative testing platform, known as IRIDICA (currently in development), produces results consistent with the . . . → Read More: Company Update: Abbott Laboratories (NYSE:ABT) – Promising Preliminary Data Show Abbott’s Innovative Testing Platform May Identify Life-Threatening Infections Faster Than Current Methods Similar Articles: Company Update (NYSE:GE): Leading forensic laboratories participate in independent validation of the GE Healthcare Life Sciences and NetBio Rapid DNA system Market Update (NASDAQ:MSFT): Microsoft delivers data platform for the era of ambient intelligence Abbott Laboratories (NYSE:ABT) – Abbott Announces FDA Approval of Its Supera® Stent to Treat People with Peripheral Artery Disease